AVAI (Avai Bio) Total Liabilities: $2.97 Mil (As of Dec. 2025)


AVAI Avai Bio Inc AVAI
24 GF Score
Price $0.15
! 3 Warning Signs
View Full Analysis

What is Avai Bio Total Liabilities?

Avai Bio AVAI -3.77% 24 Total Liabilities is $2.97 Mil as of Dec. 2025. GuruFocus rates AVAI with a GF Score™ of 24/100. The stock has 3 warning signs investors should review.

Avai Bio's Total Liabilities for the quarter that ended in Dec. 2025 was $2.97 Mil.

Avai Bio's quarterly Total Liabilities increased from Jun. 2025 ($2.14 Mil) to Sep. 2025 ($2.53 Mil) and increased from Sep. 2025 ($2.53 Mil) to Dec. 2025 ($2.97 Mil).

Avai Bio's annual Total Liabilities increased from Mar. 2023 ($0.88 Mil) to Mar. 2024 ($1.79 Mil) but then stayed the same from Mar. 2024 ($1.79 Mil) to Mar. 2025 ($1.79 Mil).

Avai Bio Total Liabilities Historical Data

* Premium members only.

The historical data trend for Avai Bio's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Avai Bio Total Liabilities Chart

Avai Bio Annual Data
Trend Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25
Total Liabilities
Get a 7-Day Free Trial 1.14 0.86 0.88 1.79 1.79

Avai Bio Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.31 1.79 2.14 2.53 2.97
AVAI
24GF Score
Avai Bio Inc AVAI
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Avai Bio Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Avai Bio's Total Liabilities for the fiscal year that ended in Mar. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=1.789+(0+0
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=1.79

Total Liabilities=Total Assets (A: Mar. 2025 )-Total Equity (A: Mar. 2025 )
=0.225--1.564
=1.79

Avai Bio's Total Liabilities for the quarter that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=2.967+(0+0
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=2.97

Total Liabilities=Total Assets (Q: Dec. 2025 )-Total Equity (Q: Dec. 2025 )
=0.173--2.794
=2.97

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of $2.97 Mil mean?
Avai Bio (AVAI) has a Total Liabilities of $2.97 Mil as of Dec. 2025. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Avai Bio and its competitors.
Is Avai Bio's Total Liabilities too high?
Avai Bio's current Total Liabilities is $2.97 Mil. Overall, Avai Bio has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does Avai Bio's Total Liabilities compare to IPM and RCT?
Avai Bio's Total Liabilities of $2.97 Mil can be compared against companies in the Software industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Software company?
A good Total Liabilities depends on the Software industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Avai Bio and its competitors. Avai Bio's current Total Liabilities is $2.97 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Avai Bio stock overvalued right now?
Avai Bio (AVAI) has a current Total Liabilities of $2.97 Mil. The current Total Liabilities is $2.97 Mil. Avai Bio's overall GF Score™ is 24/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Avai Bio (AVAI), the current Total Liabilities is $2.97 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Avai Bio Business Description

Address 5348 Vegas Drive, Las Vegas, NV, USA, 89108
Avai Bio Inc is a biotechnology company focused on identifying genetically modified cell lines, and through joint venture and licensing agreements, developing cell-based therapies. The company has two development programs in its cellular therapies pipeline, a diabetes development program to advance a treatment for type 1 and type 2 insulin-dependent diabetes, and an ?-Klotho protein development program to advance therapies for age-related diseases and anti-aging treatments.
24GF Score

Get the complete analysis for AVAI

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.15
Price